Established in 2016, Univo IRB is an Independent Review Board (IRB) focused on serving biotech and small pharma sectors. The company specializes in the ethical review of Phase I-IV pharmaceutical, device, biologic, behavioral, and psycho-social research. It prioritizes efficiency and promptness in its operations while maintaining a strong focus on advocating for patient rights throughout its processes.
Qualitas Funds' News
Return to Qualitas Funds news
Qualitas Funds IV – Univo IRB
We are pleased to announce Univo IRB has been added to the Qualitas Funds IV portfolio through the acquisition by one of our GPs in the United States.
Other news from Portfolio transactions
Qualitas Funds Direct II– Acquisition of Compass
We are pleased to announce that Compass has been added to the Qualitas Funds Direct II portfolio. This co-investment has been made with one of our GPs in the UK.
Read more
Qualitas Funds V – Acquisition of kShuttle
We are delighted to announce that kShuttle has been added to the Qualitas Funds V portfolio. This transaction was led by one of our managers located in France.
Read more